marked.bio

Company

Servier Affaires Médicales

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ivosidenib 2

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

    Active, not recruiting Phase 3 Servier Affaires Médicales Started 2023Primary completion 2027-12 NCT05876754

    ivosidenib FDA EU

    Have a documented IDH1 R132C, R132L, R132G, R132H, or R132S gene-mutated disease

    IDH1/2 mutationCholangiocarcinoma

  2. An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

    Recruiting Phase 3 Servier Affaires Médicales Started 2023Primary completion 2027-10 NCT05907057

    ivosidenib FDA EUazacitidine

    Have a documented IDH1 R132 gene-mutated disease

    IDH1/2 mutationAcute Myeloid Leukemia (AML)